Biotech ETF XBI Falls 3.27% While Five Large Sector Stocks Slip Less
State Street's biotech ETF fell 3.27% on Thursday, a deeper drop than any of five large sector stocks (down 0.22% to 1.15%). An Amgen target raise and a Gilead campaign do not explain it.

State Street SPDR S&P Biotech ETF (NYSE Arca: XBI) fell 3.27% in the regular session on Thursday, Nov. 12, closing at $151.20 against $156.31 on Wednesday. Five large stocks in the sector (Amgen, Gilead, Vertex, Regeneron and Biogen) fell between 0.22% and 1.15%. Company news was thin: an Argus Research price-target raise on Amgen and a Gilead partnership on HIV prevention awareness.
The fund fell harder than the big names
XBI lost more than any of the five large stocks, so the drop was not led by them. Neither piece of news moved those shares, and the cause of the fund's decline is not clear.
The fund started lower and stayed there
In pre-market trading (before the 9:30 a.m. ET open), XBI was down 1.26% at $153.89 from Wednesday's after-hours close. It opened 1.25% below Wednesday's close and traded between $150.50 and $154.51, ending near the bottom of that range.
Volume was 8.23 million shares, or about $1.25 billion. That is 0.94 times the 10-day average of 9.21 million shares, so the selling came on ordinary turnover.
The large stocks started the day the other way. Each opened above Wednesday's close (an opening gap) and then slid, on light volume. Relative volume compares the day's trading with the 10-day average:
- Amgen: $467.06, down 0.22% on the day, after a 0.8% gap up. Relative volume 0.42.
- Vertex: $542.62, down 0.81%, after a 0.15% gap up. Relative volume 0.55.
- Regeneron: $951.19, down 0.86%, after a 1.34% gap up. Relative volume 0.81.
- Gilead: $167.95, down 1.05%, after a 0.84% gap up. Relative volume 0.61.
- Biogen: $250.48, down 1.15%, after a 0.63% gap up. Relative volume 0.79.
XBI's last five completed sessions began with a 6.73% drop on Nov. 5 to $148.40, its largest one-day fall in the past month. It then rose 2.57% on Nov. 6 and 3.08% on Nov. 9 (to $156.90), slipped 1.17% on Nov. 10 and gained 0.81% on Nov. 11. Thursday's close is below each of the four closes from Nov. 6 to Nov. 11.
News that did not hold the shares up
Argus Research kept its Buy rating on Amgen and raised its price target to $515 from $460 on Thursday morning. Amgen rose 0.54% in pre-market trading, then fell 1.41% in the regular session from its pre-market close, after a session high of $474.00. It finished down 0.22% from Wednesday's close.
Gilead's partnership announcement came at 9:31 a.m. ET, one minute after the open. The company said it has teamed up with TelevisaUnivision and the 27th Latin GRAMMY Awards on a campaign to raise awareness of HIV prevention among Latino viewers. Gilead's decline matched the other four stocks.
What the pattern says about the sector
The five stocks have market values of $253.21 billion (Amgen), $209.91 billion (Gilead), $141.65 billion (Vertex), $98.57 billion (Regeneron) and $37.15 billion (Biogen). Their declines were mild and came on volume well below normal. Because the fund fell about three times as far as the average of these names, more of the selling happened elsewhere in the sector. Which stocks drove it is not clear.
The drop fits XBI's recent swings. Over the four weeks to Nov. 11 the fund gained 6.5%, peaked at $160.29 on Oct. 29 and had a 3.64% jump on Oct. 20 alongside the Nov. 5 drop.
Bottom line
XBI's 3.27% decline was broader than anything in the five large stocks, which fell far less on thin volume. The Amgen and Gilead news did not change that picture.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




